First Horizon Advisors Inc. increased its position in shares of Progyny, Inc. (NASDAQ:PGNY – Get Rating) by 1,469.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 769 shares of the company’s stock after acquiring an additional 720 shares during the quarter. First Horizon Advisors Inc.’s holdings in Progyny were worth $38,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Comerica Bank boosted its position in shares of Progyny by 48.2% during the 3rd quarter. Comerica Bank now owns 31,317 shares of the company’s stock valued at $1,980,000 after acquiring an additional 10,182 shares during the last quarter. Advisor Group Holdings Inc. boosted its position in shares of Progyny by 29.8% during the 4th quarter. Advisor Group Holdings Inc. now owns 43,171 shares of the company’s stock valued at $2,176,000 after acquiring an additional 9,901 shares during the last quarter. Swiss National Bank boosted its position in shares of Progyny by 0.6% during the 4th quarter. Swiss National Bank now owns 118,100 shares of the company’s stock valued at $5,946,000 after acquiring an additional 700 shares during the last quarter. Congress Wealth Management LLC DE acquired a new position in shares of Progyny during the 4th quarter valued at about $4,355,000. Finally, Liontrust Investment Partners LLP acquired a new position in shares of Progyny during the 3rd quarter valued at about $7,280,000. 82.51% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently weighed in on PGNY. TheStreet cut shares of Progyny from a “c-” rating to a “d+” rating in a research report on Friday, January 28th. Zacks Investment Research upgraded shares of Progyny from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $65.86.
Shares of NASDAQ:PGNY opened at $36.94 on Friday. The firm’s 50-day moving average is $43.58 and its two-hundred day moving average is $46.45. Progyny, Inc. has a 1 year low of $32.06 and a 1 year high of $68.32. The firm has a market capitalization of $3.40 billion, a PE ratio of 65.96, a price-to-earnings-growth ratio of 16.92 and a beta of 2.01.
Progyny (NASDAQ:PGNY – Get Rating) last released its earnings results on Monday, February 28th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.11. Progyny had a net margin of 10.09% and a return on equity of 23.15%. The firm had revenue of $127.55 million for the quarter, compared to analyst estimates of $134.87 million. During the same period in the prior year, the firm earned $0.07 earnings per share. The business’s quarterly revenue was up 27.2% compared to the same quarter last year. As a group, equities analysts forecast that Progyny, Inc. will post 0.1 earnings per share for the current fiscal year.
About Progyny (Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.